Publication

Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function

Tuininga, Y. S., Crijns, H., Oosterhuis, B., Wiesfeld, A., van Wijk, L. M., Albronda, F., de Bruin, I. D., Jonkman, J. H., Kozma, C. & Lie, K., Mar-1994, In : Journal of Cardiovascular Pharmacology. 23, 3, p. 408-414 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Tuininga, Y. S., Crijns, H., Oosterhuis, B., Wiesfeld, A., van Wijk, L. M., Albronda, F., de Bruin, I. D., Jonkman, J. H., Kozma, C., & Lie, K. (1994). Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function. Journal of Cardiovascular Pharmacology, 23(3), 408-414.

Author

Tuininga, Y.S. ; Crijns, H. ; Oosterhuis, B ; Wiesfeld, A. ; van Wijk, L. M. ; Albronda, F ; de Bruin, I.D. ; Jonkman, J.H. ; Kozma, C. ; Lie, K. / Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function. In: Journal of Cardiovascular Pharmacology. 1994 ; Vol. 23, No. 3. pp. 408-414.

Harvard

Tuininga, YS, Crijns, H, Oosterhuis, B, Wiesfeld, A, van Wijk, LM, Albronda, F, de Bruin, ID, Jonkman, JH, Kozma, C & Lie, K 1994, 'Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function', Journal of Cardiovascular Pharmacology, vol. 23, no. 3, pp. 408-414.

Standard

Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function. / Tuininga, Y.S.; Crijns, H.; Oosterhuis, B; Wiesfeld, A.; van Wijk, L. M.; Albronda, F; de Bruin, I.D.; Jonkman, J.H.; Kozma, C.; Lie, K.

In: Journal of Cardiovascular Pharmacology, Vol. 23, No. 3, 03.1994, p. 408-414.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Tuininga YS, Crijns H, Oosterhuis B, Wiesfeld A, van Wijk LM, Albronda F et al. Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function. Journal of Cardiovascular Pharmacology. 1994 Mar;23(3):408-414.


BibTeX

@article{9ac803abde20487b9b500dd1f125c78a,
title = "Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function",
abstract = "The hemodynamic and pharmacokinetic effects of the novel class 1c antiarrhythmic drug restacorin were investigated in two groups of patients. Group I consisted of 5 patients with normal left ventricular (LV) function, and group II consisted of 10 patients with mild heart failure [New York Heart Association (NYHA) II; mean LV ejection fraction 33 +/- 6%]. The study had an open label, baseline-controlled, single-dose design. Restacorin was infused in a total dosage of 1.2 mg/kg. In group I, the only significant change as compared with baseline findings was a 25% increase in right atrial pressure. In group II; cardiac output (CO), dP/dt, and stroke work index (SWI) decreased significantly (-18, -11, and -24%, respectively). In addition, a significant 32% increase was noted in pulmonary artery wedge pressure (PAWP), and a 27% increase occurred in systemic vascular resistance (SVR). No changes were observed in heart rate (HR) or mean arterial blood pressure (MAP). CO and SVR at baseline correlated with the average plasma concentrations (r = -0.65 and p = 0.009 and r = 0.56 and p = 0.028 respectively). Creatinine clearance was inversely correlated to the restacorin plasma concentration (r = -0.51, p = 0.05). The half-life (t1/2) elimination time of restacorin was 2.60 h for group I, and 4.06 h for group II. Clearance was 51.4 and 32.2 L.h(-1), respectively. Restacorin appears to be well tolerated in patients with normal LV function. The drug is not recommended for use in patients with reduced LV function because of its moderate negative inotropic effect.",
keywords = "ANTIARRHYTHMIC, LEFT VENTRICULAR FUNCTION, HEMODYNAMICS, INOTROPY, CONGESTIVE-HEART-FAILURE, ACUTE MYOCARDIAL-INFARCTION, ANTI-ARRHYTHMIC AGENT, FLECAINIDE, ENCAINIDE, DISOPYRAMIDE, DISEASE",
author = "Y.S. Tuininga and H. Crijns and B Oosterhuis and A. Wiesfeld and {van Wijk}, {L. M.} and F Albronda and {de Bruin}, I.D. and J.H. Jonkman and C. Kozma and K. Lie",
year = "1994",
month = mar,
language = "English",
volume = "23",
pages = "408--414",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
number = "3",

}

RIS

TY - JOUR

T1 - Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function

AU - Tuininga, Y.S.

AU - Crijns, H.

AU - Oosterhuis, B

AU - Wiesfeld, A.

AU - van Wijk, L. M.

AU - Albronda, F

AU - de Bruin, I.D.

AU - Jonkman, J.H.

AU - Kozma, C.

AU - Lie, K.

PY - 1994/3

Y1 - 1994/3

N2 - The hemodynamic and pharmacokinetic effects of the novel class 1c antiarrhythmic drug restacorin were investigated in two groups of patients. Group I consisted of 5 patients with normal left ventricular (LV) function, and group II consisted of 10 patients with mild heart failure [New York Heart Association (NYHA) II; mean LV ejection fraction 33 +/- 6%]. The study had an open label, baseline-controlled, single-dose design. Restacorin was infused in a total dosage of 1.2 mg/kg. In group I, the only significant change as compared with baseline findings was a 25% increase in right atrial pressure. In group II; cardiac output (CO), dP/dt, and stroke work index (SWI) decreased significantly (-18, -11, and -24%, respectively). In addition, a significant 32% increase was noted in pulmonary artery wedge pressure (PAWP), and a 27% increase occurred in systemic vascular resistance (SVR). No changes were observed in heart rate (HR) or mean arterial blood pressure (MAP). CO and SVR at baseline correlated with the average plasma concentrations (r = -0.65 and p = 0.009 and r = 0.56 and p = 0.028 respectively). Creatinine clearance was inversely correlated to the restacorin plasma concentration (r = -0.51, p = 0.05). The half-life (t1/2) elimination time of restacorin was 2.60 h for group I, and 4.06 h for group II. Clearance was 51.4 and 32.2 L.h(-1), respectively. Restacorin appears to be well tolerated in patients with normal LV function. The drug is not recommended for use in patients with reduced LV function because of its moderate negative inotropic effect.

AB - The hemodynamic and pharmacokinetic effects of the novel class 1c antiarrhythmic drug restacorin were investigated in two groups of patients. Group I consisted of 5 patients with normal left ventricular (LV) function, and group II consisted of 10 patients with mild heart failure [New York Heart Association (NYHA) II; mean LV ejection fraction 33 +/- 6%]. The study had an open label, baseline-controlled, single-dose design. Restacorin was infused in a total dosage of 1.2 mg/kg. In group I, the only significant change as compared with baseline findings was a 25% increase in right atrial pressure. In group II; cardiac output (CO), dP/dt, and stroke work index (SWI) decreased significantly (-18, -11, and -24%, respectively). In addition, a significant 32% increase was noted in pulmonary artery wedge pressure (PAWP), and a 27% increase occurred in systemic vascular resistance (SVR). No changes were observed in heart rate (HR) or mean arterial blood pressure (MAP). CO and SVR at baseline correlated with the average plasma concentrations (r = -0.65 and p = 0.009 and r = 0.56 and p = 0.028 respectively). Creatinine clearance was inversely correlated to the restacorin plasma concentration (r = -0.51, p = 0.05). The half-life (t1/2) elimination time of restacorin was 2.60 h for group I, and 4.06 h for group II. Clearance was 51.4 and 32.2 L.h(-1), respectively. Restacorin appears to be well tolerated in patients with normal LV function. The drug is not recommended for use in patients with reduced LV function because of its moderate negative inotropic effect.

KW - ANTIARRHYTHMIC

KW - LEFT VENTRICULAR FUNCTION

KW - HEMODYNAMICS

KW - INOTROPY

KW - CONGESTIVE-HEART-FAILURE

KW - ACUTE MYOCARDIAL-INFARCTION

KW - ANTI-ARRHYTHMIC AGENT

KW - FLECAINIDE

KW - ENCAINIDE

KW - DISOPYRAMIDE

KW - DISEASE

UR - https://www.ncbi.nlm.nih.gov/pubmed/7515984

M3 - Article

VL - 23

SP - 408

EP - 414

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -

ID: 6378672